1. Diabetes Canada Clinical Practice Guidelines Expert Committee. (2018). Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes; 42(Suppl 1): S1-325.
2. Berlin DA, Gulick RM, Martinez FJ. (2020). Severe Covid-19. N Engl J Med 383: 2451-60
3. Conway SJ, Izuhara K, Kudo Y and et al. (2014). The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci; 71(7):1279–1288.
4. Snider P, Standley KN, Wang J, et al. (2009). Origin of cardiac fibroblasts and the role of periostin. Circ Res; 105(10):934–947.
5. Azharuddin M, Adil M, Ghosh Pand et al. (2019). Periostin as a novel biomarker of cardiovascular disease: a systematic evidence landscape of preclinical and clinical studies. J Evid Base Med; 12(4):325–336.
6. Luo Y, Qu H, Wang H and et al. (2016). Plasma periostin levels are increased in Chinese subjects with obesity and type 2 diabetes and are positively correlated with glucose and lipid parameters. Mediat Inflamm; 2016(6423637):1-6.
7. Dong D, Jia L, Zhang L et al. (2018). Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer. Cancer Sci; 109(9):2841-2851.
8. Liu Y, Li F, Gao F and et al. (2017). Role of microenvironmental periostin in pancreatic cancer progression. Oncotarget; 8(52):89552-89565.
9. Satirapoj B, Tassanasorn S, Charoenpitakchai M and et al. (2015). Periostin as a tissue and urinary biomarker of renal injury in type 2 diabetes mellitus. PLoS One 10:e0124055.
10. Yoshida S, Ishikawa K, Asato R and et al. (2011). Increased expression of periostin in vitreous and membranes obtained from patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci; 52:5670–5678.
11. Ohta S, Okamoto M, Fujimoto K and et al. (2017). The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis. PLoS One. 2017; 12(3):e0174547.
12. Liu AY, Zheng H, Ouyang G. Periostin. (2014). A multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix Biol; 37: 150-156.
13. Takayama G, Arima K, Kanaji T and et al. (2006). Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol; 118: 98-104.
14. Conway SJ, Izuhara K, Kudo Y and et al. (2014). The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci; 71: 1279-1288.
15. Kazakou P, Paschou SA, Psaltopoulou T, et al.(2021). Early and Late Endocrine Complications of COVID-19. Endocr Connect; 10(9):R229–39..
16. Lim S, Bae JH, Kwon H-S, et al. (2021). COVID-19 and Diabetes Mellitus: From Pathophysiology to Clinical Management. Nat Rev Endocrinol; 17(1):11–30.
17. Apicella M, Campopiano MC, Mantuano M and et al. (2020). COVID-19 in People With Diabetes: Understanding the Reasons for Worse Outcomes. Lancet Diabetes Endocrinol; 8(9):782–92.
18. Drucker DJ. (2020). Coronavirus Infections and Type 2 Diabetes—Shared Pathways With Therapeutic Implications. Endocr Rev; 41(3):457–70.
19. Cabalak M, Doğan S, Bal T et al. (2021). Serum periostin levels in COVID-19: Is it useful as a new biomarker?. Int J Clin Pract; 00:e14728: 1-6.
20. Fayez, S.S., Rashied, R.M., Al-Alaaraji, S.F.T. (2020). Evaluation of serum clusterin levels in type 2 diabetic men with and without cardiovascular disease. Iraqi Journal of Science, 61(5): 978–984.
21. Abbas, K.M., Alaaraji, S.F.T., Al – Shawk, R.S. (2020). Astudy of the association between IL-17 and HOMA-IR in Iraqi type 2 diabetic patients. Iraqi Journal of Science, 61(3): 491–498.
22. Zhang N, Wang C, Zhu Fand et al. (2020). Risk Factors for Poor Outcomes of Diabetes Patients with COVID-19: a Single-Center, Retrospective Study in Early Outbreak in China. Front Endocrinol; 24 (11):571037.
23. Gupta S, Hayek SS, Wang W and et al. (2020). Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. JAMA Intern Med; 180(11):1436–1447.
24. Petrilli CM, Jones SA, Yang J and et al. (2020). Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ; 369:m1966..
25. Tang N, Li D, Wang X, Sun Z. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost; 18(4):844–847.
27. Lang LW, Zhu ZZ,, Xu Zand et al.(2022). The Association Between the Albumin and Viral Negative Conversion Rate in Patients Infected with Novel Coronavirus Disease 2019 (COVID-19). Infection and Drug Resistance: 15 1687–1694.
28. Polito C, Martin GS. (2013). Albumin: physiologic and clinical effects on lung function. Minerva Anestesiol; 79(10):1180–1186.
29. Huang W, Li C, Wang ZQ and et al. (2020). Decreased serum albumin level indicates poor prognosis of COVID-19 patients: hepatic injury analysis from 2623 hospitalized cases. Sci China Life Sci; 63(11):1678–1687.
30. Aldecoa C, Llau JV, Nuvials X and et al. (2020). Role of albumin in the preservation of endothelial glycocalyx integrity and the microcirculation: a review. Ann Intensive Care; 10(85):1-12.